Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

APE2 Score

SD Siqi Ding
JG Jiaoni Gong
JL Jiahe Lin
YW Yi Wang
YH Yingjie Hua
XL Xueying Li
YD Yanru Du
NX Niange Xia
ZZ Zhenguo Zhu
XW Xinshi Wang
RZ Rongyuan Zheng
HX Huiqin Xu
request Request a Protocol
ask Ask a question
Favorite

The initial version of the Antibody Prevalence in Epilepsy (APE) score was established by Dubey as a model to predict the detection of neural Abs in autoimmune epilepsy patients based on clinical manifestations and initial neurologic evaluations (7). An APE score of ≥4 had a sensitivity and specificity of 82.6 and 82.0%, respectively, and can be used as a tool for identifying patients for Ab testing (7). After three modifications, the APE2 scoring system has a higher specificity for the prediction of neural autoantibody positivity (from 78 to 84%) among patients with epilepsy, without a loss in sensitivity (98%) (9). The determination of the APE2 score in patients with encephalopathy or cognitive decline to predict AE-related Ab positivity showed that an APE2 score ≥4 was 99% sensitive and 93% specific for neural-specific Abs (8).

Copyright and License information:  ©2021 Ding, Gong, Lin, Wang, Hua, Li, Du, Xia, Zhu, Wang, Zheng and Xu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A